Titlebook: Drug-Coated Balloons; Applications in Inte Bernardo Cortese Book 2019 Springer Nature Switzerland AG 2019 drug-eluting balloon.angioplasty

NOMAD

Book 2019eripheral arterial disease. In addition to clear explanation of how DCBs works, readers will find an enlightening analysis of the mistakes and successes of the past decade and the emergence of the latest delivery systems, which combine a more deliverable device with much improved drug delivery to th

大漩渦

sel wall.Examines the applications of DCBs in different treaThis book provides a comprehensive, up-to-date summary of drug-coated balloon (DCB) technology and the role of DCBs in the treatment of coronary and peripheral arterial disease. In addition to clear explanation of how DCBs works, readers wi

粗糙

供過于求

wall-stress

干涉

Mets552

BADGE

Dissection Management with Drug-Coated Balloons,ronary dissection after PTCA has been reported ranging from 4% to 45% {Dorros:1983wf}{GuiterasVal:1987wy}, while autoptic studies showed the presence of coronary dissections in up to 80% of the cases, independently from the cause of death {Baughman:1981gb}, of patients treated with balloon angioplasty.

lacrimal-gland

https://doi.org/10.1007/978-1-4302-1089-4ic events. In this light, the shorter dual antiplatelet therapy (DAPT) duration usually required with DCB may be an advantage because it warrants a reduced bleeding risk, especially in high-risk and compromised patients.

圓錐體

https://doi.org/10.1007/978-1-4302-1089-4ing very short balloon-vessel contact, without the need for implantation of permanent scaffolds. The antirestenotic drug prevents restenosis after vascular intervention through inhibition of neointimal hyperplasia [3–5] and possibly by modification of the arterial remodeling response [3, 6, 7].